AstraZeneca, HealthCore CER Collaboration Will Look at Genomically Defined Subpopulations | GenomeWeb

Originally published Feb. 15.

By Turna Ray

By joining with national payor WellPoint to conduct comparative effectiveness studies, AstraZeneca will get access to HealthCore's vast enrollee database, which may allow the drug developer to advance more pharmacogenomically guided treatments.

Earlier this month, AstraZeneca announced it was working with WellPoint's research subsidiary HealthCore to conduct CER that would inform its pipeline.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.